https://medicalhub.camurus.com/https://medicalhub.camurus.com/disease-areas/https://medicalhub.camurus.com/disease-areas/acromegaly/https://medicalhub.camurus.com/page-footer/https://medicalhub.camurus.com/congresses/https://medicalhub.camurus.com/congresses/2026/albatros-2026/https://medicalhub.camurus.com/congresses/2026/ece-2026/https://medicalhub.camurus.com/congresses/2026/ice-2026/https://medicalhub.camurus.com/congresses/2026/endo-2026/https://medicalhub.camurus.com/congresses/2025/joint-congress-of-european-society-for-paediatric-endocrinology-espe-and-european-society-of-endocrinology-ese-2025/https://medicalhub.camurus.com/congresses/2025/american-association-of-clinical-endocrinology-aace-annual-meeting-2025/https://medicalhub.camurus.com/congresses/2025/endo-2025/https://medicalhub.camurus.com/congresses/2025/enea-workshop-2025/https://medicalhub.camurus.com/congresses/2024/26th-european-congress-of-endocrinology-ece-2024/https://medicalhub.camurus.com/publications/https://medicalhub.camurus.com/publications/2025/results-from-the-core-phase-of-the-open-label-phase-3-acroinnova-2-trial-cam2029-a-subcutaneous-octreotide-depot-achieves-sustained-long-term-biochemical-control-in-acromegaly/https://medicalhub.camurus.com/publications/2025/cam2029-a-self-administered-subcutaneous-octreotide-depot-improved-pros-and-symptoms-in-patients-with-acromegaly-in-the-acroinnova-2-phase-3-trial-final-analysis-of-the-core-phase-results/https://medicalhub.camurus.com/publications/2025/cam2029-octreotide-subcutaneous-depot-provides-stable-control-of-igf-i-and-improves-key-symptoms-throughout-a-4-week-post-dose-interval-analysis-from-the-acroinnova-1-trial/https://medicalhub.camurus.com/publications/2025/cam2029-an-octreotide-subcutaneous-depot-provides-long-term-and-sustained-biochemical-control-of-acromegaly-final-analysis-of-the-core-part-of-the-acroinnova-2-phase-3-trial/https://medicalhub.camurus.com/publications/2025/improved-patientreported-outcomes-with-cam2029-treatment-an-octreotide-subcutaneous-depot-in-patients-with-acromegaly-previously-on-standard-of-care-injectable-somatostatin-receptor-ligands-final-analysis-of-the-core-part-of-the-acroinnova-2-phase-3-trial/https://medicalhub.camurus.com/publications/2025/cam2029-octreotide-subcutaneous-depot-maintains-control-of-igf-i-and-symptoms-of-acromegaly-across-the-4-week-dosing-interval-and-during-intervals-greater-than-28-days-data-from-the-acroinnova-1-trial/https://medicalhub.camurus.com/publications/2025/population-pharmacokinetic-analysis-of-an-octreotide-depot-cam2029-in-the-treatment-of-acromegaly/https://medicalhub.camurus.com/publications/2025/cam2029-an-octreotide-subcutaneous-fluidcrystal-depot-provides-biochemical-control-of-acromegaly-and-improves-patient-reported-outcomes-interim-results-from-the-phase-3-acroinnova-2-trial/https://medicalhub.camurus.com/publications/2025/cam2029-octreotide-subcutaneous-depot-maintains-control-of-igf-i-and-symptoms-of-acromegaly-across-a-4-week-dosing-interval-and-for-intervals-greater-than-28-days-data-from-the-acroinnova-1-trial/https://medicalhub.camurus.com/publications/2025/long-term-and-sustained-biochemical-control-of-acromegaly-and-improved-quality-of-life-with-cam2029-octreotide-subcutaneous-depot-final-analysis-of-the-core-phase-of-acroinnova-2/https://medicalhub.camurus.com/publications/2024/octreotide-subcutaneous-depot-for-acromegaly-a-randomized-double-blind-placebo-controlled-phase-3-trial-acroinnova-1/https://medicalhub.camurus.com/publications/2024/preferences-for-different-treatment-options-among-people-living-with-acromegaly-in-the-us/https://medicalhub.camurus.com/science/https://medicalhub.camurus.com/science/rd-pipeline/https://medicalhub.camurus.com/science/technology/https://medicalhub.camurus.com/cookie-policy/https://medicalhub.camurus.com/page-not-found/https://medicalhub.camurus.com/resources/https://medicalhub.camurus.com/contact/https://medicalhub.camurus.com/search-results/https://medicalhub.camurus.com/login/https://medicalhub.camurus.com/register/https://medicalhub.camurus.com/posteraccess/enea2025/https://medicalhub.camurus.com/posteraccess/enea2025/igf-1-stability/https://medicalhub.camurus.com/posteraccess/enea2025/biochemicalcontrol/https://medicalhub.camurus.com/posteraccess/obap-study-2025/https://medicalhub.camurus.com/posteraccess/aace2026/https://medicalhub.camurus.com/posteraccess/aace2026/demographic-and-clinical-characteristics/https://medicalhub.camurus.com/posteraccess/ece-2026/https://medicalhub.camurus.com/posteraccess/ece-2026/acroinnova-2-extension/https://medicalhub.camurus.com/posteraccess/ece-2026/acroinnova-2-igf-1-stability/https://medicalhub.camurus.com/posteraccess/ece-2026/acroinnova-2-directly-enrolled/